Our highly-experienced Board has a track record of developing products in the life science and healthcare industry and of successfully selling Australian companies to US-based acquirers.

Paul MacLeman


Paul has over 25 years experience across the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Paul has expertise in capital raising, business development, technology commercialisation, and sales and marketing. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Paul has previously served as Managing Director and/or CEO of several VC funded, ASX, NASDAQ and TSX listed companies. Paul is also current Chairman of LiVac Pty Limited and is an Executive Director of AusCann Holdings Limited and Non-Executive Director of Sypharma Pty Limited.

Tim Oldham PhD


Tim has more than 15 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical product. Tim was appointed CEO and MD in October 2019. Immediately prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim CEO, executive and non-executive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. Prior to this, Tim was an engagement manager with McKinsey & Co. Industry leadership roles include currently serving as a Director of BioMelbourne Network Inc and terms as chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine and a Director of the Generic Medicines Industry Association. He is a Non-executive Director at Acrux Ltd (ASX:ACR).

Liddy McCall


Liddy is co-founder of 3 biotechnology companies successfully achieving 3 FDA drug registrations and 1 FDA/CE Mark medical device approval.  She is an inventor on patents granted in major jurisdictions translating novel G-protein coupled pharmacology into a therapeutic drug treatment currently in Phase 2 clinical trials.  Liddy co-founded IIF venture capital fund, Yuuwa Capital LP, which is responsible for a portfolio of 6 companies commercializing biotechnology and IT innovation.  Liddy has over 25 years of experience in senior Board and management roles including iCeutica Inc group (acquired in 2011 achieving a ten-fold uplift on the valuation of the company), Dimerix Bioscience Pty Ltd (now Dimerix Limited ASX:DXB) and  iCetana Pty Ltd.  Liddy was an Associate Director in the Corporate Advisory Group of Macquarie Bank and prior to that worked as a lawyer with a leading Australian law firm.  She has qualifications in law and finance. Liddy is on the Board of Ear Science Institute Australia and a non-executive director of Adalta Limited, Agworld Pty Ltd, Nexgen Plants Pty Ltd and The Tailor Made Spirits Company Limited.

James Williams PhD


James is a co-founder and Investment Director of Yuuwa Capital LP, a venture capital firm based in Western Australia. Prior to Yuuwa Capital, he was Managing Director of two medical device companies, ASX-listed Resonance Health Ltd and Argus Biomedical Pty Ltd, both of which secured regulatory approvals under his leadership. He conceived, co-founded and is a former CTO and Director of iCeutica, Inc., a clinical stage nano drug delivery company. iCeutica was acquired by Philadelphia-based Iroko Pharmaceuticals in 2011. Iroko received FDA approval for the first three iCeutica formulations between 2013 and 2015. James is Chairman of ASX-listed clinical stage drug discovery and development company Dimerix Ltd (ASX:DXB) and Director of Yuuwa investee companies PolyActiva Pty Ltd and iCetana Pty Ltd. He is also a Director of Linear Clinical Research Ltd, a specialist early phase clinical trial unit, a member of the “Panel of Experts” for the University of Western Australia’s Pathfinder Fund and a member of the Australian Federal Government’s Entrepreneur Program Committee.

Robert Peach PhD


Dr Peach has over 25 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry.  In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings.  In August 2015 Receptos was acquired by Celgene for $7.8B.  Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments.  His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs.  He currently serves on the Board of Directors of Innate Immunotherapeutics and Avalia Immunotherapies and is a consultant for several other biotechnology companies. Robert is the co-author of 70 scientific publications and book chapters, and 17 patents.  He was educated at the University of Canterbury and the University of Otago, New Zealand.

David Fuller


David has 30 years experience in pre-clinical, clinical development, medical and regulatory affairs with a specialisation in the early phase development of biological impressive record of developing and commercialising new products and establishing and nurturing businesses in complex international environments. He has led five product approvals in the United States (US) and European Union (EU) for orphan and major market products, together with multiple Regulatory Agency (US/EU) interactions including Investigational New Drug (IND) applications. David has designed and executed multiple Phase I – III studies in US, EU and Asia across multiple therapeutic areas. David is currently Senior Vice President, Clinical Development, Oncology Business Unit, Syneos Health where he has overall responsibility for the strategy and growth of the Oncology Business Unit in Asia Pacific. He is also a Non-Executive Director at EpiAxis Therapeutics Pty Ltd, a former Non-Executive Director of Linear Clinical Research Ltd – a Perth based clinical trials facility – and a former Chair of Dimerix Ltd (ASX:DXB). David holds Bachelor of Medicine/Bachelor of Surgery and Bachelor of Pharmacy degrees from University of Sydney.

Cameron Jones


Cameron Jones is a Chartered Accountant and holds a Certificate in Governance (Practice) from the Governance Institute of Australia and assumes responsibility for Australian Securities and Investments (ASIC) reporting, ASX compliance and reporting, planning and execution of annual reporting and shareholder meetings as well as Chief Financial Officer of AdAlta. Cameron is also a Director of Bio101Group Pty Ltd, a wholly owned subsidiary of Biotech Capital Limited and has previously worked at Pitcher Partners.